Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $5.17.

A number of research firms recently commented on SGMO. Wells Fargo & Company reduced their target price on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 31st. Jefferies Financial Group reduced their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, December 31st. Truist Financial reduced their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research note on Monday, January 27th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $2.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock opened at $0.87 on Friday. The stock has a market cap of $180.81 million, a P/E ratio of -1.16 and a beta of 1.49. Sangamo Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.18. The firm’s fifty day moving average price is $1.07 and its 200-day moving average price is $1.41.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The firm had revenue of $7.55 million during the quarter, compared to the consensus estimate of $11.70 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. Sell-side analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Institutional Trading of Sangamo Therapeutics

Several institutional investors have recently added to or reduced their stakes in SGMO. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Sangamo Therapeutics by 12.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 122,463 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 13,518 shares during the period. LPL Financial LLC boosted its holdings in shares of Sangamo Therapeutics by 113.5% during the fourth quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 16,498 shares during the period. Northern Trust Corp boosted its holdings in shares of Sangamo Therapeutics by 4.5% during the fourth quarter. Northern Trust Corp now owns 398,289 shares of the biopharmaceutical company’s stock worth $406,000 after purchasing an additional 17,049 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Sangamo Therapeutics by 679.5% during the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 21,793 shares during the period. Finally, E Fund Management Co. Ltd. purchased a new stake in shares of Sangamo Therapeutics during the fourth quarter worth about $25,000. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.